<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740168</url>
  </required_header>
  <id_info>
    <org_study_id>B-ANF1</org_study_id>
    <nct_id>NCT00740168</nct_id>
  </id_info>
  <brief_title>Bevacizumab Treatment and Retinal Vessel Monitoring</brief_title>
  <acronym>BevaRet</acronym>
  <official_title>Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab might influence the dynamic vessel function after being administered
      intravenously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel
      analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter of retinal vessels and dynamic vessel reaction</measure>
    <time_frame>Measurements before and after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baroreflex sensitivity, heart frequence variability, reaction to handgrip test</measure>
    <time_frame>Measurements before and after administration</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>TG</arm_group_label>
    <description>Bevacizumab treatment group with metastasized cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab treatment</intervention_name>
    <description>single infusion 10 mg/kg</description>
    <arm_group_label>TG</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>ATC code: L01XC07</other_name>
    <other_name>CAS Registry Number:216974-75-3</other_name>
    <other_name>VEGF-inhibitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients with first bevacizumab treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who wish and need bevacizumab treatment for underlying disease

        Exclusion Criteria:

          -  previous bevacizumab treatment

          -  known eye disease, eye surgery or eye trauma in history

          -  myopia &gt;-2.0 dpt

          -  hyperopia &gt; +2.0 dpt.

          -  relevant media opacity of the lens

          -  acute heart disease, ischemic insult, proven coronary heart disease

          -  cardiac arrhythmia or vessel anomalies

          -  seizure disorder or episode in history

          -  migraine

          -  treatment with corticosteroids within 4 weeks before study inclusion

          -  intake of vasoactive drugs like AT-1 or glitazone

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tjalf Ziemssen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurological University Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Autonomic lab (ANF)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

